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Summary 
Objectives: Valproic acid (VPA) induced adverse effects, which are sometimes serious in 
children, can be associated with alterations in VPA metabolism. VPA-evoked toxicity is 
attributed to both the parent compound and its unsaturated metabolites, primarily formed by 
CYP2C9 enzyme. Thus, patients’ CYP2C9-status may account for the predisposition to 
adverse reactions, and testing CYP2C9-status may contribute to the improvement and 
rationalization of VPA therapy in children. 
Methods: In CYPtest group, children’s CYP2C9-status was screened before initiating 
antiepileptic therapy. CYP2C9-status was estimated by the identification of defective CYP2C9 
allelic variants (CYP2C9*2, CYP2C9*3) and current CYP2C9 expression in patients’ 
leukocytes which reflects hepatic CYP2C9 activities. Combining the results of CYP2C9 
genotyping and CYP2C9 expression, the patients’ VPA-metabolizing capacity was predicted, 
and VPA dosing was adjusted to the patients’ CYP2C9-status. Clinical and biochemical 
parameters, such as VPA serum levels, blood cell counts, liver function parameters, adverse 
effects in patients of CYPtest group were compared with those of the control group treated 
with VPA according to conventional clinical practice. 
Results: CYP2C9-guided treatment significantly reduced VPA-misdosing and consequently 
decreased the ratio of patients out of the range of target VPA blood concentrations. In CYPtest 
group of children receiving CYP2C9-status adapted dose, serum alkaline phosphatase (ALP) 
and the ratio of patients with abnormal ALP levels were substantially lower than in the control 
group. The incidence of serious side effects, notably hyperammonemia, was reduced in 
CYPtest group; however, some other side effects, such as weight changes and somnolence, 
could not be avoided. 
Significance: The knowledge of pediatric patients’ CYP2C9-status can contribute to the 
optimization of VPA dosing and to the avoidance of misdosing-induced side effects. 
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CYP2C9 genotype, CYP2C9 expression 
  
Introduction 
 Since its introduction as an antiepileptic drug, valproate (VPA) became one of the first 
choices in treatment of generalized or partial seizures. VPA is well-tolerated; however, serious 
complications, including hepatotoxicity, hyperammonemic encephalopathy, bone marrow 
suppression, and bone metabolic disorders, rarely occur in patients.1 Infants are particularly 
vulnerable to VPA-injury, although the pathogenesis is still not clear.2,3 Genetic and non-
genetic factors may increase the predisposition to VPA-induced adverse reactions; thus, 
recognition of risk factors can contribute to the avoidance of adverse events. 
 In adult patients on VPA monotherapy, the majority of the dose is eliminated as 
glucuronide-conjugates. Mitochondrial β-oxidation, producing unsaturated VPA-metabolites, 
is the second major metabolic pathway. About 15-20% of VPA-dose is metabolized by 
cytochrome P450 (CYP) enzymes, resulting in the formation of 4-ene-VPA and hydroxy-
metabolites.4 The main catalyst of hydroxylation and desaturation to 4-ene-VPA is CYP2C9 
with minor contribution of CYP2A6 and CYP2B6.5,6 Although the mechanism of VPA-
induced adverse effects is not clearly understood, the parent compound and its unsaturated 
metabolites are postulated to be associated with VPA toxicity.7 Despite the fact that CYP-
mediated oxidation contributes to a minor part of VPA-metabolism in adults, in children the 
CYP-catalyzed pathways become the principal route of metabolism. It is supported by the facts 
that i) hepatic glucuronidation activities are low in infants, primarily in children younger than 
two years of age, and UDP-glucuronyl transferases involved in VPA-conjugation are expressed 
under adult levels until sometimes after 10-15 years of age;8,9 ii) VPA and some VPA-
metabolites inhibit mitochondrial β-oxidation;10,11 iii) CYP-dependent metabolism in children 
exceeds adult activities and decreases to adult levels by puberty.12,13 As a result, larger 
proportion of VPA is liable to CYP-dependent metabolism in children than in adults, which 
explains the increase in VPA clearance and toxic metabolite formation in pediatric patients. At 
therapeutic doses, VPA elimination half-life is substantially shorter (6-9 hours) in children 
than in adults (10-20 hours).14 Furthermore, shifting the metabolic pathways may lead to age-
related differences in the incidence of adverse reactions. 
 Several CYP2C9 allelic variants, resulting in the synthesis of non-functional CYP2C9 
enzyme, have been identified with the highest frequency of CYP2C9*2 and CYP2C9*3 in 
Caucasian population.15 Patients with mutated genes are permanent poor metabolizers, whereas 
those with wild-type alleles (CYP2C9*1/*1) have the potential for the expression of functional 
enzyme. However, environmental (nutrition, medication) or internal factors (age, diseases) can 
transiently modulate CYP2C9 expression, leading to altered CYP2C9 activities and transient 
poor (or extensive) metabolism, even in the patients with CYP2C9*1/*1 genotype. As a 
consequence of genetic and non-genetic variations, a patient’s drug-metabolizing capacity can 
be weaker (or more extensive) compared with the other members of the population.16 Patients’ 
CYP2C9-status can be estimated by the identification of defective CYP2C9 alleles and by 
current CYP2C9 expression. We have previously described that CYP2C9 expression in 
leukocytes of those subjects who do not carry loss-of-function mutations reflects the hepatic 
tolbutamide hydroxylation activity selective for CYP2C9.17 CYP2C9-genotyping for 
CYP2C9*2 and CYP2C9*3 identifies the genetically determined poor metabolism, whereas 
CYP2C9 expression in leukocytes of patients with wild-type alleles estimates reduced or even 
increased CYP2C9 activity resulted in by non-genetic variations. We have reported in a 
retrospective study that children’s CYP2C9-status influences the serum VPA concentrations 
and consequently the dose-requirements.18 For optimal therapeutic levels, the VPA dose-
requirement was substantially higher (33 mg/kg) in normal expressers carrying CYP2C9*1/*1 
genotype than in low expressers or in patients carrying any polymorphic CYP2C9 alleles (14–
17 mg/kg). Our present work aimed to prospectively investigate whether preliminary assaying 
of CYP2C9-status and CYP2C9-status guided VPA therapy have potential clinical benefit for 
pediatric patients, and whether personalized drug therapy can reduce the risk of VPA-
misdosing induced adverse reactions. 
Methods 
Patients and sampling procedure 
 Pediatric patients (N=99) suffering from epilepsy diagnosed with partial or generalized 
seizures were enrolled in the study carried out at Heim Pál Children's Hospital and at the 2nd 
Department of Pediatrics, Semmelweis University (Budapest, Hungary). We recruited patients, 
younger than 15 years of age, who were newly-diagnosed with epilepsy and were to be applied 
VPA therapy. The patients were excluded if their VPA therapy was interrupted. The patients’ 
clinical data were collected between 2006 and 2014. From 2010, each child was CYP2C9-
tested at the beginning of antiepileptic therapy. CYPtesting of patients was approved by the 
Hungarian Committee of Science and Research Ethics. The representatives of each patient 
gave their informed consent to participate in the study. The patients’ demographic data (Table 
1) and the details of anticonvulsant therapy were recorded. The patients were not given any 
other medication, but VPA as mono-therapy (Convulex or Depakine). The hematological (red 
and white blood cell and platelet counts) and biochemical parameters (serum alkaline 
phosphatase, aspartate transaminase, alanine transaminase, γ-glutamyl transferase, calcium, 
phosphorus) were checked at the beginning of the anticonvulsant therapy and monitored 
regularly. Blood ammonia level was not routinely assayed, only if any symptom reasoned it. 
All signs of adverse reactions due to the VPA treatment were reported, and were classified as 
mild (somnolence, fatigue, enuresis, hair loss) or severe (hyperammonemia, hematological 
disorders, confusion) side effects.  
CYP2C9-testing 
 In CYPtest group, the patients’ CYP2C9-status was determined by CYP2C9 
genotyping and by assaying CYP2C9 expression in leukocytes before the beginning of 
anticonvulsant therapy. Genomic DNA and leukocytes were isolated from the samples of 
peripheral blood according to the methods described by Temesvári et al.17 CYP2C9 
genotyping was carried out by hydrolysis single-nucleotide-polymorphism analysis for 
CYP2C9*2 and CYP2C9*3 using TaqMan Probes (BioSearch Technologies, Novato CA). For 
assaying CYP2C9 expression, total RNA was isolated from leukocytes, RNA was reverse-
transcribed into single-stranded cDNA, and real-time PCR with human cDNA was performed 
using UPL probe for CYP2C9 (Roche Diagnostics, Mannheim, Germany). The quantity of 
CYP2C9 mRNA relative to that of the housekeeping gene glyceraldehyde 3-phosphate 
dehydrogenase was determined. Three categories of CYP2C9 expression were distinguished to 
describe low, normal and high expressers. The cutoff values for the CYP2C9 mRNA levels in 
leukocytes were previously established on the basis of the cutoff values for the hepatic 
CYP2C9 activity (tolbutamide hydroxylation), allowing a distinction between low, normal 
(medium) and high expressers (5*10-6 and 2.5*10-5, respectively).17 
VPA dosing 
 In CYPtest group (N=52), the patients’ anticonvulsant therapy was guided by their 
CYP2C9-status: i) non-VPA therapy was proposed to the children with two mutated CYP2C9 
alleles, ii) and VPA therapy adjusted to the patients’ CYP2C9-status (CYP2C9 genotype and 
CYP2C9 expression) was applied in those with one or two wild-type alleles.18 Normal dose 
(30-40 mg/kg) was given to the normal CYP2C9 expresser patients carrying CYP2C9 
homozygous wild genotype (CYP2C9*1/*1), reduced dose (10-20 mg/kg) was administered to 
the children with heterozygous genotypes (CYP2C9*1/*2 or CYP2C9*1/*3), or to low 
CYP2C9 expressers, while increased dose (>40 mg/kg) was targeted in high expresser patients 
with CYP2C9*1/*1 genotype. In control group (N=47), the target dose of VPA was adjusted to 
the patients’ body weight (20-40 mg/kg) according to the standard clinical protocol, and was 
modified if the signs of adverse reactions or non-responsiveness required.19  
 
Serum VPA assay 
 The blood samples for drug assays were taken from the patients before the morning 
dose and VPA concentrations were assayed every second week after the beginning of VPA 
treatment. The steady-state serum concentration of VPA was determined by fluorescence 
polarization immunoassay method (AxSYM Valproic Acid Assay, Abbott Laboratoties, IL). 
The VPA concentrations between 40 and 100 µg/ml were considered to be in the reference 
range.19 The two-week sample was used for checking VPA serum concentration, and dose was 
modified if exposure was outside the target range. The serum levels measured at the fourth 
week were considered to be the stable steady-state concentration, and the dose prescribed at 
this time was considered to be the maintenance dose. 
Statistical analysis 
Statistical analysis of biochemical and hematological parameters as well as VPA serum 
levels was carried out using GraphPad Instat (v3.05, GraphPad Software, San Diego, CA). 
Parameter distributions were analyzed by Kolmogorov-Smirnov test. Between-group 
differences were calculated by Mann-Whitney U-test. The benefit of CYP2C9-status guided 
VPA therapy over the classical dosing was also evaluated comparing the ratio of patients with 
therapeutic VPA serum levels, normal hematological or biochemical parameters in CYPtest 
group with those in control group. The frequencies of adverse events were also compared. The 
differences between CYPtest and control groups were calculated by Fisher’s exact test. A P 
value of <0.05 was considered statistically significant. 
  
Results 
Assaying CYP2C9-status of pediatric patients 
 Because of homozygous mutant genotype (CYP2C9*2/*2), one of the CYPtested 
children was excluded from the study, and non-VPA therapy was applied. All of the remaining 
patients in CYPtest group (N=51) expressed at least one wild-type CYP2C9 allele 
(CYP2C9*1), and more than one quarter of patients carried one of the polymorphic CYP2C9 
variants (CYP2C9*2 or CYP2C9*3) (Table 1). The CYP2C9 genotype frequencies of 
CYP2C9*1/*2 and CYP2C9*1/*3 in the patients (13.5% and 11.5%, respectively) were similar 
to those in Caucasian populations.15 CYP2C9 expression assay displayed low expressers in 
two thirds of patients with homozygous wild genotype (CYP2C9*1/*1) (Table 1). Subjects 
with two wild-type alleles are generally considered to be extensive metabolizers; however, low 
CYP2C9 expression was predicted to result in poor VPA metabolism in patients.18 The 
unusually high ratio of low expressers was attributed to down-regulation of CYP2C9 
expression by cytokine release in epilepsy.18 Nine children with heterozygous CYP2C9 
genotypes (CYP2C9*1/*2 or CYP2C9*1/*3) expressed CYP2C9 mRNA at normal levels, 
although they were considered to be poor metabolizers because they carried merely one mutant 
allele, resulting in reduced CYP2C9 function. Of 51 children in CYPtest group, altogether 38 
patients (25 low expressers with CYP2C9*1/*1 genotype and 13 patients carrying 
heterozygous genotype) were expected to have poor VPA metabolizing capacity. 
Potential benefit of CYP2C9-status guided VPA therapy 
 For 74.5% of the patients in CYPtest group, who were low CYP2C9 expressers or 
normal expressers with mutant CYP2C9 alleles, reduced VPA dose (10-20 mg/kg) was 
targeted; whereas normal target dose (30-40 mg/kg) was administered to the normal expresser 
patients with CYP2C9*1/*1 genotype (23.5% of the patients) and increased dose (>40 mg/kg) 
was applied to the high expresser child carrying CYP2C9*1/*1 genotype. Despite the fact that 
reduced VPA dose was administered to most of the children in CYPtest group, the therapeutic 
efficacy (seizure frequency) was similar to those in the control group of patients on 
conventional VPA therapy. Although the average VPA serum concentrations in CYPtest group 
did not differ significantly from those in control group (Table 2), the CYP2C9-status guided 
VPA dosing substantially reduced the number of patients displaying VPA serum levels out of 
the therapeutic range (9/51 vs 21/47) (Figure 1). Moreover, the deviation of VPA 
concentrations from the therapeutic range (40 to 100 µg/ml) was significantly lower in the 
CYPtest group than in the control group (Table 2).  
 For recognizing the early signs of adverse reactions, biochemical and hematological 
parameters were followed in both groups from the beginning of anticonvulsant therapy. Before 
the beginning of antiepileptic therapy, the liver function parameters, serum levels of calcium 
and phosphorus as well as red blood cell, white blood cell and platelet counts were in the 
reference ranges in all patients. One month after the beginning of VPA therapy, no significant 
alterations were observed in red or white blood cell and platelet counts. Biochemical 
parameters of patients in both groups were also in reference ranges, except for the alkaline 
phosphatase (Table 2). The patients in the control group displayed a significant increase in 
serum alkaline phosphatase activity which is generally associated with either hepatotoxicity or 
bone metabolic disorders. Nevertheless, the levels of neither serum transaminases and 
γ-glutamyl transferase nor calcium and phosphorus in control patients differed from those 
parameters in CYPtest group. Serum alkaline phosphatase levels show great variation with age 
in children20; however, the substantial increase within one month was rather attributed to VPA 
treatment than to the transient hyperphosphatasemia. The age of the control patients were 
considered to be similar to that of the children in CYPtest group, whereas serum alkaline 
phosphatase activities exceeded the normal range in almost half of the control patients and 
merely in 4% of CYPtested patients. Furthermore, VPA-associated serious adverse effects 
were observed more frequently in the control group than in the CYPtest group (Table 3). 
Hyperammonemia (>50 µmol/l), the most frequent side effect in control patients (17%), was 
always accompanied with elevated levels of alkaline phosphatase (higher than 750 unit/l or 
even more than 1200 unit/l) and with other adverse reactions, such as somnolence, fatigue, 
consciousness or behavior disturbances. Furthermore, serum VPA concentrations in the 
patients with increased ammonia levels were found to be higher than 100 µg/ml. It should be 
mentioned that the prevalence of mild side effects, including weight gain, hair loss, enuresis 
and somnolence was similar in the control and CYPtest groups (Table 3). 
 
Discussion 
 VPA has therapeutic benefits with a favorable safety profile, being well-tolerated in 
most patients; however, considerable attention has been paid to age-related differences in the 
incidence of VPA-associated adverse events.7,9,12 Metabolic differences between children and 
adults, resulting in various developmental pattern in biotransformation, may play role in 
different side effect profiles. Several authors described the changes in VPA metabolic profile 
from childhood to adolescence and adulthood.7,9,21,22 Glucuronide formation as the major 
metabolic pathway of VPA has been reported to be much lower in children than in 
adolescents.23 Altered β-oxidation of VPA in pediatric patients, resulting in distinct metabolite 
profiles, have also been associated with liver dysfunction.21,23 Assigning a prominent role in 
VPA metabolism to CYP2C9 in children, genetic variations in CYP2C9 as the potential risk 
factors have been considered to contribute to VPA-induced toxicity.5,6,24 Ho et al. 
demonstrated that VPA metabolizing activity was substantially lower in hepatic microsomes 
expressing CYP2C9*2 or CYP2C9*3 than the wild-type allele.5 Statistically significant 
increase in VPA plasma concentrations was displayed in Chinese patients carrying CYP2C9*3 
allele24; however, the moderate differences may be attributed to the fact that the authors did not 
take the age-related variations in VPA metabolism into account. In contrast, Guo et al. did not 
find any obvious impact of CYP2C9*3 mutation on VPA plasma concentrations and dose-
requirements in Chinese pediatric patients25, most likely because the authors neglected 
CYP2C9 expression in patients. Our previous work has clearly demonstrated that CYP2C9-
status of children younger than 15 years of age was associated with VPA dose-requirements 
for the optimal serum VPA levels.18 The loss-of-function mutations in CYP2C9 gene 
(CYP2C9*2 or CYP2C9*3) resulting in poor metabolism can lead to high blood concentrations 
of certain drugs (e.g. VPA, warfarin, hypoglycaemic drugs), causing more severe and frequent 
side effects14,26-28; however, we consider low CYP2C9 expression to be an additional risk 
factor for undesired side effects of VPA in children.18 Increased sensitivity of children to VPA 
can be explained by the poor glucuronidation of VPA, shifting the metabolic pathways towards 
CYP2C9-mediated metabolism and by the genetic and non-genetic factors influencing 
CYP2C9 activity; thus, personalized VPA therapy adjusted to the patients’ CYP2C9-status is 
recommended. 
 Hematological disorders, hepatotoxicity and hyperammonemia are rare adverse effects 
induced by VPA exposure, but sometimes result in fatalities.1,2,7,21,23 VPA is hypothesized to 
have direct toxicity on bone marrow, whereas VPA itself and some of its metabolites might be 
involved in liver injury.1,7,22 According to the CYP2C9-status guided anticonvulsant 
therapeutic strategy, non-VPA treatment is proposed to children carrying CYP2C9 alleles with 
two loss-of-function mutations (CYP2C9*2/*2, CYP2C9*3/*3 or CYP2C9*2/*3) to avoid 
adverse reactions, whereas refinement of VPA dosing is proposed for those carrying one or 
two wild-type CYP2C9 alleles.18 The conventional dosing approach, targeting VPA daily dose 
of 20 to 40 mg/kg, has been found to be appropriate merely for normal CYP2C9 expressers 
with CYP2C9*1/*1 genotype, whereas low expressers or children with one wild-type CYP2C9 
allele have been demonstrated to require substantially reduced dose.18 CYP2C9*1/*1 genotype, 
predicted to be translated to an extensive metabolizer phenotype, can be switched into poor 
metabolism due to phenoconversion, which eventually influences the manifestation of VPA 
side effects.16 Furthermore, the genotype-phenotype mismatch results in more poor 
metabolizers than it would be predicted from CYP2C9 genotype. Several external or internal 
factors, including co-medications, nutrition, disease or hormonal changes, modifying the 
expression and activity of CYP2C9 enzyme, can give rise to phenoconversion of patients’ 
CYP2C9*1/*1 genotype.16 Nevertheless, the variability of CYP2C9 expression in the children 
can hardly be explained by co-medications, because the patients on multi-drug therapy were 
excluded from the study. The down-regulation of CYP2C9 expression by pro-inflammatory 
cytokines released in patients following seizures is a logical explanation for poor 
metabolism.29 Due to the wide range of the children’s age, various hormonal statuses could 
also be the factor resulting in the variability of CYP2C9 expression.30 However, we could 
detect all these influences by measuring CYP2C9 mRNA levels in the patients of CYPtest 
group and adjusted VPA dosing to their CYP2C9 expression. The conventional VPA-based 
antiepileptic therapy would have been inappropriate for most of the CYP2C9-tested children in 
the present study: one child carrying CYP2C9*2/*2 would have poorly tolerated VPA, and 
75% of the patients in CYPtest group would have been misdosed. Since the routine protocol of 
the conventional therapy orders checking VPA blood concentrations three to four weeks after 
the beginning of VPA therapy, there is no other guide, but symptoms that can inform about 
VPA-misdosing.19 Therefore, much caution is recommended in clinical and biochemical 
monitoring of patients primarily during the dose escalation. 
 The benefit of CYP2C9-status guided VPA dosing over the symptom-driven therapy 
was clearly demonstrated by more precise VPA dosing and by successfully reduced risk of side 
effects. In CYPtest group, the knowledge of patients’ CYP2C9-status before the beginning of 
anticonvulsant therapy guided the selection of the appropriate drug and the optimal dose. 
CYP2C9-status controlled VPA therapy improved the achievement of target VPA serum levels 
resulting in fewer patients out of the therapeutic range of serum VPA concentrations. 
Moreover, alkaline phosphatase activity was significantly lower (in normal range) in the 
children on CYP2C9-status controlled therapy than in the patients on conventional symptom-
driven therapy. Abnormalities in serum alkaline phosphatase are considered to be associated 
with bone metabolic disorders or hepatotoxicity. Decreased bone mineral density accompanied 
with reduced bone formation has been reported in children on long-term (more than six-month) 
VPA therapy.31 The patients of the present study received VPA for only one month, and the 
serum concentrations of calcium and phosphorus were in normal range; thus, increased levels 
of serum alkaline phosphatase in control patients might be the marker of other 
pathomechanisms. Hyperammonemia, which is associated with impaired urea cycle in liver32, 
was frequently observed in the control children, and always accompanied with extremely 
elevated levels of alkaline phosphatase and increased serum concentrations of VPA 
(>100 mg/ml) in patients. An increase in blood ammonia level has poor predictive value for 
hepatotoxicity; thus, it was not routinely determined for recognizing hepatotoxicity. However, 
elevated blood ammonia level, often without an increase in liver function parameters, is 
associated with VPA-induced encephalopathy. The blood ammonia level is recommended to 
be measured if patients present any of the symptoms of nausea, vomiting, lack of appetite, 
fatigue, drowsiness, confusion, cognitive slowing or loss of consciousness.33 At least one of 
these symptoms was observed in the hyperammonemic children in this study. 
 Our present work is the first attempt to establish the influence of the genetic and non-
genetic variations of CYP2C9 on VPA metabolism. Our major findings indicated that 
personalized anticonvulsant therapy can be applied in pediatric patients by revealing the allelic 
variants in CYP2C9 gene and the current CYP2C9 expression in patients’ leukocytes. 
CYP2C9-status guided VPA treatment could prevent patients from misdosing and from 
exaggerated serum concentrations of VPA, resulting in the manifestation of toxic symptoms, 
such as increased alkaline phosphatase and hyperammonemia. Tailored VPA treatment 
adjusted to the patients’ CYP2C9-status has been demonstrated to be able to improve the 
safety of anticonvulsant therapy in one of the most vulnerable patient populations. 
Key points 
• In pediatric patients, the metabolic pathways of valproic acid seem to be shifted 
towards the CYP2C9-catalyzed oxidation. 
• Inferring the patients’ valproate metabolizing phenotype from CYP2C9 genotype and 
CYP2C9 expression can lead to appropriate prediction. 
• The children’s CYP2C9-status influenced the serum valproate concentrations and 
consequently the dose-requirements. 
• Patients’ CYP2C9-status accounts for the predisposition to some adverse reactions such 
as increased alkaline phosphatase or hyperammonemia. 
• CYP2C9-status guided refinement of valproate therapy can contribute to the avoidance 
of misdosing-induced side effects in children. 
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 Table 1. Demographic data of pediatric patients involved in the study. 
Patients Number of patients Age (year)* 
Body weight 
(kg)* Boys/girls 
Control group 47 8 (0.13 – 15) 27 (4.6 – 62) 31/16 
CYPtest group 52 6.25 (0.5 – 15) 21 (6 – 67.5) 24/28 
  CYP2C9*1/*1     Normal expressers 12 4 (0.5 – 11) 15 (6 – 32) 4/8 
Low expressers 25 7 (0.6 – 15) 25 (7 – 67.5) 12/13 
High expressers 1 4.5 15 1/- 
  CYP2C9*1/mut  Normal expressers 9 4 (3 – 15) 19 (14.5 – 52) 5/4 
Low expressers 4 7.5 (4 -15) 22.5 (15 – 60) 1/3 
  CYP2C9*2/*2 1 7 25 1/- 
*: median (range); CYP2C9*1/mut: CYP2C9*1/*2 or CYP2C9*1/*3 
 
  
Table 2. Patients’ clinical parameters (VPA serum concentration, hematological and liver 
function parameters, calcium and phosphorus levels, incidence of side effects) one month after 
the beginning of VPA treatment.  
Parameter 
Control group 
(N=47) 
CYPtest group 
(N=51) 
Significance 
VPA concentration (µg/ml) 85.0±36.02 72.0±21.05 ns 
Ratio of patients out of the VPA 
therapeutic range 
21/47 9/51 P=0.004 
Deviation from the VPA therapeutic 
concentration (µg/ml) 
21.2±16.17 2.98±1.90 P<0.001 
Alkaline phosphatase (unit/l) 545.1±235.81 236.0±138.76 P<0.001 
Ratio of patients with alkaline 
phosphatase exceeding the normal range 
23/47 2/51 P<0.001 
Aspartate aminotransferase (unit/l) 27.3±9.77 27.5±8.66 ns 
Alanine aminotransferase (unit/l) 16.1±7.93 15.8±8.50 ns 
γ-glutamyl transferase (unit/l) 15.6±7.02 14.3±8.51 ns 
Calcium (mmol/l) 2.23±0.434 2.41±0.121 ns 
Phosphorus (mmol/l) 1.64±0.533 1.52±0.297 ns 
Red blood cell count (x1012/l) 4.5±0.48 4.6±0.46 ns 
White blood cell count (x109/l) 7.0±2.19 7.9±3.22 ns 
Platelet count (x109/l) 227.1±88.06 245.4±70.81 ns 
ns: not significant (P>0.05) 
  
Table 3. Incidence of side effects one month after the beginning of VPA treatment.  
Side effects 
Control group 
(N=47) 
CYPtest group 
(N=51) 
Significance 
Serious: 14/47 2/51 P<0.001 
Hyperammonemia 8/47 1/51 P=0.01 
Nausea 1/47 1/51 ns 
Thrombocytopenia 2/47 0/51 ns 
Purple spots on the skin 1/47 0/51 ns 
Confusion, loss of consciousness 2/47 0/51 ns 
Mild: 18/47 10/51 P=0.05 
Hair loss 3/47 2/51 ns 
Somnolence 6/47 4/51 ns 
Enuresis 2/47 1/51 ns 
Fatigue 3/47 1/51 ns 
Changes in appetite, weight gain 3/47 2/51 ns 
Mood swings 1/47 0/51 ns 
ns: not significant (P>0.05) 
  
  
 
 
 
 
 
Figure 1. Serum VPA concentrations in pediatric patients one month after the beginning of 
VPA treatment. (Control group N=47, CYPtest group N=51) Therapeutic VPA concentration 
range is marked between 40 and 100 µg/ml. 
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